Aspirin

Search ⌘K Suggest Edit Sign in Names and Branding Chemical and Physical Properties History Pharmacology Medical Uses Administration and Dosages Adverse Effects and Safety Other Applications References Fact-checked by Grok 4 months ago Aspirin Aspirin, chemically known as acetylsalicylic acid, is a nonsteroidal anti-inflammatory drug (NSAID) that serves as an analgesic, antipyretic, anti-inflammatory, and antithrombotic agent, making it one of the most widely used medications worldwide for over a century.[1] Derived from salicylic acid found in willow bark, it is available in various forms including tablets, capsules, and suppositories, with typical doses ranging from low-strength 81 mg for cardiovascular protection to higher 325–650 mg for pain relief.[2] Its molecular formula is C₉H₈O₄, and it appears as an odorless white crystalline powder with a slightly bitter taste.[1] The history of aspirin traces back more than 3,500 years to ancient Sumerians and Egyptians who used willow bark extracts for pain and fever reduction.[2] In the 19th century, the active compound salicylic acid was isolated, and acetylsalicylic acid was first synthesized in 1853 by French chemist Charles Frédéric Gerhardt, though it was not stable for commercial use until Felix Hoffmann at Bayer developed a purer form in 1897, leading to its market introduction as Aspirin in 1899.[2] Its mechanism of action was elucidated in the 1970s, revealing its role in inhibiting key enzymes involved in inflammation and clotting.[2] Aspirin exerts its effects primarily through irreversible acetylation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby blocking the synthesis of prostaglandins and thromboxanes that mediate pain, fever, inflammation, and platelet aggregation.[2] For antithrombotic purposes, low doses inhibit thromboxane A2 production in platelets, reducing blood clot formation without significantly affecting vascular prostacyclin.[1] Clinically, it is indicated for relieving mild to moderate pain from headaches, arthritis, and menstrual cramps; reducing fever; treating inflammatory conditions like osteoarthritis and rheumatoid arthritis; and preventing cardiovascular events such as myocardial infarction, ischemic stroke, and angina in select at-risk patients. It is established for secondary prevention in patients with established cardiovascular disease. For primary prevention in those without prior disease, low-dose aspirin is not routinely recommended due to bleeding risks often outweighing benefits. According to the 2022 USPSTF guideline, which remains the current authoritative recommendation as of 2026 with no new guidelines issued in 2025 or 2026, the decision to initiate low-dose aspirin for the primary prevention of CVD in adults aged 40 to 59 years with a 10% or greater 10-year CVD risk should be individualized (Grade C recommendation; small net benefit), while the USPSTF recommends against initiating low-dose aspirin for primary prevention in adults aged 60 years or older (Grade D recommendation; harms outweigh benefits). The 2019 ACC/AHA guideline suggests that low-dose aspirin might be considered (Class IIb) for select adults aged 40 to 70 years at higher ASCVD risk without increased bleeding risk. Risk stratification tools such as coronary artery calcium scoring may help identify those with higher CAC scores (≥100) who are more likely to benefit.[3][4][5][6] Despite its efficacy, aspirin carries notable risks, including gastrointestinal adverse effects such as ulcers, bleeding, and perforation due to reduced mucosal protection from prostaglandin inhibition.[2] It is associated with hypersensitivity reactions in 1–2% of users, exacerbated asthma in sensitive individuals, and a rare but serious risk of Reye's syndrome in children and adolescents with viral infections, prompting contraindication in this group.[2] High doses may cause tinnitus, hearing loss, or metabolic disturbances like acidosis, while chronic use requires monitoring of salicylate levels to avoid toxicity.[4] Contraindications include active peptic ulcer disease, bleeding disorders, severe renal or hepatic impairment, and concurrent use with certain anticoagulants without medical supervision.[2][3] Names and Branding Generic and Brand Names The generic name for the drug commonly known as aspirin is acetylsalicylic acid, a salicylate compound used as a nonsteroidal anti-inflammatory drug (NSAID).[7] This name reflects its chemical structure, derived from acetylation of salicylic acid.[2] In medical and pharmaceutical contexts, "aspirin" is widely accepted as the nonproprietary name, particularly since it entered common usage before the establishment of formal international nonproprietary names (INN) by the World Health Organization, where pre-existing names like aspirin were retained due to their established recognition.[8] Aspirin was originally trademarked by Bayer in 1899 as a brand name for acetylsalicylic acid, but the term has since become genericized in many countries, allowing production by multiple manufacturers.[9] In the United States, it is available under numerous over-the-counter and prescription brand names, often formulated for specific uses such as pain relief, cardiovascular protection, or buffered to reduce stomach irritation.[3] Common U.S. brand names include: Bayer Aspirin (low-dose and regular strength for cardiovascular and pain relief) Ecotrin (enteric-coated for reduced gastrointestinal side effects) Bufferin (buffered formulation) Durlaza (extended-release for antiplatelet therapy) Vazalore (liquid-filled capsules) Aspir 81 (low-dose for heart health) Arthritis Pain (targeted for inflammatory conditions) Aspirina (introduced in 2025 for pain relief, adapted from the Mexican market)[10] These brands vary in dosage forms, such as tablets, chewables, or extended-release capsules, and are approved by the FDA for indications including analgesia, antipyresis, and antithrombotic effects.[11][12] Internationally, acetylsalicylic acid is marketed under additional brand names reflecting regional preferences and formulations, such as Adiro (Germany), Aspro (Australia and UK), and Nu-Seals (UK for enteric-coated versions).[7] In combination products, it appears in brands like Aggrenox (with dipyridamole for stroke prevention) and Yosprala (with omeprazole for gastroprotection).[7] The diversity of names underscores aspirin's global availability as both a standalone generic and in proprietary blends.[11] Historical Naming and Trademarks The name "Aspirin" was coined in 1899 by Heinrich Dreser, head of Bayer's pharmacological laboratory, deriving from the "a" prefix for acetyl, "spir" from the plant genus Spiraea (meadowsweet, a historical source of salicylic acid), and the common pharmaceutical suffix "-in".[13] This branding reflected the drug's chemical origins as acetylsalicylic acid, first synthesized by Felix Hoffmann at Bayer on August 10, 1897.[14] Bayer registered "Aspirin" as a trademark on March 6, 1899, at the Imperial Patent Office in Berlin (registration number 36433), marking it as a branded preparation of acetylsalicylic acid rather than a generic term.[14] The company quickly expanded international protection, filing for a U.S. patent on the synthesis process in 1898 (granted as U.S. Patent 644,077 in 1900) and a British patent in 1899 (GB 189909123A).[14][15] By the early 20th century, "Aspirin" had become Bayer's flagship trademark, sold initially as a powder in glass bottles and later in tablet form from 1900 onward, establishing global recognition for the pain-relief drug.[13] However, World War I disrupted Bayer's control, as Allied powers seized German assets, including intellectual property. Under the 1919 Treaty of Versailles, Germany renounced industrial property rights in favor of the Allied nations, leading to the confiscation of Bayer's trademarks in multiple countries.[16] In the United States, the Alien Property Custodian seized Bayer's U.S. operations in 1917, auctioning the Aspirin trademark and related patents to Sterling Drug Inc. for $5.3 million in 1918 (equivalent to about $100 million today).[17] This loss, compounded by the expiration of the core U.S. patent in 1917, allowed generic manufacturers to produce and market acetylsalicylic acid under the "Aspirin" name, transforming it into a genericized term in the U.S. and several other nations by the 1920s.[15][18] Post-war, Bayer retained the Aspirin trademark in Germany and some other markets but faced ongoing challenges elsewhere, where the name entered the public domain and lost exclusive association with the brand.[14] Efforts to repurchase rights began in the interwar period and continued into the late 20th century; notably, in 1994, Bayer reacquired the U.S., Canadian, and Puerto Rican Aspirin trademarks from SmithKline Beecham (via its purchase of Sterling Winthrop's over-the-counter business) for $1 billion as part of a broader deal, restoring exclusive use of "Bayer Aspirin" in those territories.[17][13] Today, while Bayer holds the trademark in over 100 countries, "aspirin" remains a generic descriptor for acetylsalicylic acid in places like the U.S., illustrating the enduring impact of wartime asset seizures on pharmaceutical branding.[14] Chemical and Physical Properties Chemical Structure and Synthesis Aspirin, chemically known as acetylsalicylic acid, has the molecular formula C₉H₈O₄ and a molecular weight of 180.157 g/mol.[1] It is classified as a benzoic acid derivative, specifically 2-(acetyloxy)benzoic acid according to its IUPAC name.[1] The core structure consists of a benzene ring substituted with a carboxylic acid group (-COOH) at position 1 and an acetoxy group (-OCOCH₃) at position 2, making it an ester of salicylic acid and acetic acid. This ortho-substituted arrangement is crucial for its pharmacological properties, as the acetoxy group modifies the phenolic hydroxyl of salicylic acid, reducing gastric irritation while preserving anti-inflammatory activity.[7] The molecule features key functional groups: the carboxylic acid, which imparts acidity (pKa ≈ 3.5), the ester linkage, and the aromatic ring, contributing to its stability and UV absorption above 290 nm.[1] In its solid form, aspirin exists as colorless or white crystals, often in monoclinic or needle-like morphology, with no odor or a slight acidic taste.[1] The structure can be represented as: \chemfig ∗ ∗ 6 ( − 𝐶 ( = 𝑂 ) 𝑂 𝐻 ) − 𝑂 − 𝐶 ( = 𝑂 ) − 𝐶 𝐻 3 \chemfig∗∗6(−C(=O)OH)−O−C(=O)−CH 3 ​

where the benzene ring is attached to the carboxylic acid and the ester side chain at adjacent positions.[1] The synthesis of aspirin involves the acetylation of salicylic acid, a process first achieved in pure form by Felix Hoffmann at Bayer in 1897 to address the tolerability issues of salicylic acid.[19] Hoffmann heated salicylic acid with acetic anhydride, yielding acetylsalicylic acid through esterification of the phenolic hydroxyl group.[19] This reaction proceeds via nucleophilic acyl substitution, where the phenolate oxygen attacks the carbonyl of acetic anhydride, releasing acetate as a leaving group.[20] Industrially, the synthesis is conducted by mixing salicylic acid with acetic anhydride (often in slight molar excess) and a catalyst such as sulfuric acid, heating the mixture to 70–90 °C to complete the reaction, then cooling to promote crystallization, followed by filtration, washing with water, and drying to yield high-purity product.[21] Alternative methods, such as using acetyl chloride, have been explored but are less common due to the corrosiveness of the reagent.[20] This straightforward acetylation remains the primary route for commercial production, patented by Bayer in 1899.[19] Synthesis of aspirin is not safe to perform at home. The process requires handling hazardous reagents, including acetic anhydride (flammable, corrosive, causes severe skin burns and eye damage, and produces irritating vapors that require a fume hood for safe handling), salicylic acid (an irritant), and sulfuric acid (highly corrosive, causes severe skin burns and eye damage). Home environments typically lack the necessary safety equipment, such as fume hoods, proper ventilation, and personal protective gear, increasing the risk of chemical burns, respiratory irritation, eye damage, and exposure to toxic fumes. Additionally, aspirin synthesized without professional purification, quality control, and testing is likely to contain impurities or contaminants and is unsafe for consumption.[22][23][24] Physical Properties and Polymorphism Acetylsalicylic acid, the active ingredient in aspirin, appears as a white, crystalline powder or as crushed, irregular-shaped crystals in its commercial form. It has a melting point of 134–136 °C and a density of approximately 1.35–1.40 g/cm³. The compound is weakly acidic with a pKa of 3.5 at 25 °C and exhibits low solubility in water, approximately 3–4.6 mg/mL at 25 °C or 0.33–0.46 g/100 g at 298 K, though solubility increases with temperature to about 10 mg/mL at 37 °C. It is more soluble in organic solvents such as ethanol (around 20 g/100 g), chloroform (6 g/100 g), and ethyl ether.[20][25][26] Aspirin is known for its polymorphism, with four known crystal forms, though only a few are stable under ambient conditions. The most stable and commercially predominant form is Form I, first characterized in 1964 and confirmed in 1985, featuring a monoclinic crystal structure with specific hydrogen bonding patterns that contribute to its thermodynamic stability. Form II, initially observed in the 1960s but fully characterized in 2005, is metastable and converts to Form I over time; it differs in molecular arrangement, with altered layer stacking and orientation of the hydroxyl group, leading to distinct spectroscopic signatures.[26][27] A third ambient polymorph, Form IV, was discovered in 2017 through crystallization from the melt, exhibiting a unique structure determined via X-ray powder diffraction and solid-state NMR, though it is less stable than Form I. High-pressure conditions yield Form III at around 2 GPa, which reverts to Form I upon decompression. Polymorphic differences significantly affect physical behaviors: Form II displays a higher dissolution rate—up to 50% faster than Form I in aqueous media—due to variations in surface energy and hydrogen bonding, impacting bioavailability and tablet compaction properties, while Form I's lower energetic state ensures its prevalence in pharmaceutical production. No hydrates of aspirin have been identified.[26][28][29] Stability and Degradation Acetylsalicylic acid is stable in dry air but gradually hydrolyzes to salicylic acid and acetic acid when exposed to moisture. In solid dosage forms, this hydrolysis is significantly accelerated by higher relative humidity (RH), as moisture facilitates the hydrolytic cleavage of the ester bond. To minimize degradation and maintain product integrity, storage at low relative humidity in tightly closed containers protected from moisture is recommended.[30][20] History Early Discovery and Development The use of willow bark for pain relief and fever reduction dates back more than 3,500 years, with evidence from Sumerian and Egyptian civilizations employing it as an analgesic and antipyretic.[31] In ancient Greece, Hippocrates prescribed willow bark preparations in the 5th century BC to alleviate labor pains and reduce fevers, marking one of the earliest documented medical applications.[32] This natural remedy's active component, salicin, was isolated in 1828 by German pharmacist Johann Andreas Buchner from willow bark extracts, while Italian chemist Raffaele Piria derived salicylic acid from it in 1838, providing the foundation for subsequent chemical investigations into salicylates.[33] By the mid-19th century, salicylic acid—derived from salicin hydrolysis—was recognized for its potent anti-inflammatory and analgesic properties, but its use was limited by severe gastric irritation.[33] In 1853, French chemist Charles Frédéric Gerhardt first synthesized acetylsalicylic acid (ASA) by reacting sodium salicylate with acetyl chloride, though the product was impure and not pursued therapeutically.[34] Efforts to mitigate salicylic acid's side effects continued, culminating in 1897 when Felix Hoffmann, a chemist at Friedrich Bayer & Co. in Germany, successfully acetylated salicylic acid to produce a stable, pure form of ASA on August 10, aiming to create a more tolerable alternative for his father's rheumatism.[19] This synthesis involved treating salicylic acid with acetic anhydride, yielding the compound now known as aspirin.[33] The development of aspirin at Bayer was a collaborative effort, with Arthur Eichengrün, head of the therapeutics department, later claiming he directed Hoffmann's work to systematically test acetylated salicylates for reduced toxicity. Eichengrün's contributions were suppressed in official Bayer narratives during the Nazi era due to his Jewish heritage and only gained wider recognition after his death in 1949 through his published account and subsequent historical analyses.[19][35] Pharmacologist Heinrich Dreser evaluated the compound's effects starting in late 1897, confirming its efficacy in animal models and human trials for pain and fever without the harsh gastrointestinal impact of salicylic acid.[19] By 1898, clinical evaluations in European clinics demonstrated aspirin's antipyretic and antirheumatic benefits, setting the stage for its broader pharmaceutical application.[19] Commercialization and Historical Uses Bayer introduced Aspirin to the market in 1899 as a stable, less irritating alternative to salicylic acid for pain relief and fever reduction. On August 10, 1897, chemist Felix Hoffmann at Bayer's laboratory in Wuppertal, Germany, synthesized the first pure and stable form of acetylsalicylic acid, motivated in part by his father's arthritis.[36] The company registered "Aspirin" as a trademark on March 6, 1899, with the Imperial Patent Office in Berlin, deriving the name from "a" for acetyl, "spir" from the Spiraea plant (a source of salicin), and the common drug suffix "-in."[14] Initially marketed as a powder, it transitioned to tablet form in 1900, with Bayer securing a U.S. patent (No. 644,077) that year to protect its production process. Early clinical testing, directed by Arthur Eichengrün and confirmed by Heinrich Dreser, demonstrated its efficacy against rheumatism and fever, leading to its rapid adoption as an over-the-counter remedy.[19] Bayer's marketing efforts propelled Aspirin to global prominence, making it one of the first mass-marketed pharmaceuticals. The company launched an aggressive international campaign, emphasizing its purity and reliability, which resulted in Aspirin becoming a bestseller in pharmacies worldwide by the early 1900s.[9] By 1950, it earned a Guinness World Record as the most frequently sold painkiller, reflecting sales driven by direct-to-consumer advertising in print media.[9] However, World War I disrupted Bayer's monopoly; in 1917, the U.S. government seized Bayer's American assets, including the Aspirin trademark and patent, allowing generic production and leading to Bayer regaining rights in 1995 through the acquisition of Sterling Winthrop's over-the-counter business after legal and commercial efforts.[14][17] Despite these setbacks, Aspirin maintained strong brand association, with surveys in the 2010s showing over 60% of U.S. consumers and nearly 80% in Germany linking it to Bayer.[36] Historically, Aspirin's uses evolved from ancient precedents to modern applications, building on millennia of willow bark remedies for analgesia and antipyresis. Upon commercialization, Bayer promoted it primarily for headaches, neuralgia, rheumatism, and influenza symptoms, with the first clinical report in 1899 confirming its antipyretic and analgesic effects without the gastric irritation of salicylic acid.[19] During World War I, it saw widespread military use for treating aches, fevers, and wounds among soldiers.[37] By the mid-20th century, its anti-inflammatory properties were recognized for conditions like arthritis, and in the 1970s, discoveries of its inhibition of prostaglandin synthesis expanded its role in preventing blood clots, marking a shift toward cardiovascular prophylaxis.[9] The World Health Organization added it to its Essential Medicines List in 1977, underscoring its enduring utility for pain, inflammation, and emerging preventive roles.[38][39] Pharmacology Mechanism of Action Aspirin, or acetylsalicylic acid, exerts its primary pharmacological effects through irreversible inhibition of the cyclooxygenase (COX) enzymes, which are critical in the biosynthesis of prostaglandins and thromboxane from arachidonic acid.[40] In 1971, John R. Vane demonstrated that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) suppress the formation of prostaglandins, mediators of pain, fever, and inflammation, by blocking COX activity in tissues such as guinea-pig lung homogenates.[41] This discovery provided the foundational understanding of aspirin's anti-inflammatory, analgesic, and antipyretic actions, earning Vane the Nobel Prize in Physiology or Medicine in 1982.[42] The inhibition occurs via covalent acetylation of a serine residue in the active site of the COX enzymes: serine 529 in COX-1 and serine 516 in COX-2.[43] Aspirin transfers its acetyl group to this serine, sterically hindering the binding of arachidonic acid and preventing the enzyme's peroxidase and cyclooxygenase activities, which convert arachidonic acid to the unstable intermediate prostaglandin H2 (PGH2).[40] Unlike reversible COX inhibitors, aspirin's acetylation leads to permanent inactivation, requiring new enzyme synthesis for recovery of activity; this effect is particularly pronounced in platelets, which lack nuclei and thus cannot replenish COX-1.[43] Aspirin is approximately 10- to 100-fold more potent against COX-1 than COX-2, though at higher doses it inhibits both isoforms.[43] This selective and irreversible mechanism underlies aspirin's diverse therapeutic roles. By inhibiting COX-1 in platelets, aspirin reduces thromboxane A2 production, a potent vasoconstrictor and platelet aggregator, thereby providing sustained antiplatelet effects that last for the platelet's lifespan (about 7-10 days).[40] In inflammatory contexts, suppression of COX-2-derived prostaglandins like PGE2 diminishes vasodilation, edema, and pain sensitization, while antipyretic effects arise from reduced PGE2-mediated elevation of the hypothalamic temperature set point.[42] At low doses (e.g., 75-325 mg daily), the impact is predominantly on COX-1 with minimal gastrointestinal effects, whereas higher doses engage both enzymes more broadly.[43] Pharmacokinetics Aspirin, or acetylsalicylic acid, exhibits rapid and nearly complete absorption following oral administration, primarily in the stomach and upper small intestine via passive diffusion as the undissociated form, with peak plasma concentrations of its primary metabolite, salicylic acid, occurring within 1 to 2 hours.[1] Bioavailability ranges from 80% to 100%, though it is reduced by presystemic hydrolysis in the gastrointestinal tract and liver, where approximately 50% of the dose is converted to salicylic acid during absorption; factors such as gastric pH, food intake, and formulation (e.g., enteric-coated tablets) can delay or alter this process, with absorption half-life typically 5 to 16 minutes.[44][2] Once absorbed, aspirin is quickly distributed throughout the body, including crossing the blood-brain barrier, placenta, and into breast milk, with a volume of distribution of approximately 0.15 L/kg for aspirin itself and up to 0.17 L/kg for salicylic acid at therapeutic doses.[45] Salicylic acid, the active form, is highly bound to plasma proteins (50-90%, primarily albumin), with binding decreasing at higher concentrations due to saturation, leading to increased free drug and potential toxicity; this concentration-dependent binding contributes to the drug's nonlinear pharmacokinetics.[1] The elimination half-life of intact aspirin is short, approximately 15 to 20 minutes, primarily due to rapid hydrolysis by esterases in plasma, erythrocytes, and tissues.[1] Metabolism occurs predominantly in the liver, where aspirin is deacetylated to salicylic acid, which then undergoes conjugation via glycine (forming salicyluric acid, ~75% of dose) or glucuronic acid (forming phenolic and acyl glucuronides, ~25%), with minor pathways producing gentisic acid; these processes exhibit saturable kinetics at higher doses, resulting in disproportionate increases in plasma levels.[2] Excretion is mainly renal, with 80-100% of the dose eliminated in urine as metabolites and free salicylic acid over 48 hours, primarily through glomerular filtration and active tubular secretion; clearance is highly pH-dependent, increasing 10- to 20-fold in alkaline urine (pH >7) due to ionized forms being less reabsorbed, while acidic urine (pH <6) reduces excretion and prolongs half-life.[1] The half-life of salicylic acid is dose-dependent, ranging from 2 to 3 hours at low antiplatelet doses (e.g., 81 mg) to 15 to 30 hours at high analgesic doses (e.g., >2 g), reflecting zero-order elimination at therapeutic levels above 150 mcg/mL.[45] Medical Uses Pain, Fever, and Inflammation Aspirin, or acetylsalicylic acid, is a nonsteroidal anti-inflammatory drug (NSAID) primarily utilized for its analgesic, antipyretic, and anti-inflammatory properties, making it effective in managing mild to moderate pain, reducing fever, and alleviating inflammation associated with various conditions.[2] It is commonly employed to relieve pain from headaches, toothaches, menstrual cramps, muscle aches, and minor arthritis symptoms, often providing relief within 30 minutes to an hour after oral administration.[46] Aspirin is used for the relief of mild to moderate pain, including headaches; in the early 2000s, specific FDA approval was granted to Bayer for marketing Extra Strength Bayer Aspirin (500 mg buffered) for acute migraine pain under NDA 21-317 (2001), enabling targeted OTC claims for migraine treatment based on clinical evidence of efficacy in reducing migraine headache severity.[47] For fever reduction, aspirin lowers body temperature by acting on the hypothalamus, typically in doses of 325–650 mg every 4–6 hours as needed for adults.[2] Its anti-inflammatory effects are particularly beneficial in rheumatic conditions such as osteoarthritis and rheumatoid arthritis, where it helps reduce joint swelling and stiffness at higher doses of 3–5 grams per day in divided doses.[46] The therapeutic actions of aspirin for pain, fever, and inflammation stem from its irreversible inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are responsible for the synthesis of prostaglandins—lipid mediators that sensitize pain receptors, elevate the hypothalamic temperature set point, and promote inflammatory responses.[42] This mechanism, first elucidated by John Vane in 1971, prevents the formation of pro-inflammatory prostaglandins like PGE2 and PGI2, thereby blocking the peripheral and central pathways that amplify nociception and pyrexia.[42] At anti-inflammatory doses, aspirin also modulates the lipoxygenase pathway, leading to the production of anti-inflammatory mediators such as lipoxins, resolvins, and maresins, which further resolve inflammation.[2] Clinical efficacy for these indications is well-established, with aspirin demonstrating superiority over placebo in reducing pain intensity, fever, and inflammatory symptoms in conditions like upper respiratory tract infections and acute musculoskeletal injuries.[48] For instance, single doses of 500–1000 mg have been shown to effectively lower fever and associated discomfort comparably to acetaminophen, with onset of action within 15–30 minutes and duration of 4–6 hours.[49] In chronic inflammatory diseases, sustained use at therapeutic levels achieves approximately 90% inhibition of COX activity, providing symptomatic relief, though it is generally less potent than modern NSAIDs for severe inflammation due to its gastrointestinal side effects.[2] Despite its efficacy, aspirin should be used cautiously in children and adolescents with viral illnesses due to the risk of Reye's syndrome, and its antipyretic use is not recommended for fever alone in otherwise healthy individuals.[46] Cardiovascular Prevention Low-dose aspirin (typically 75–100 mg daily, most commonly 81 mg in the US) serves as the gold standard for secondary cardiovascular prevention, supported by decades of large-scale randomized controlled trials and meta-analyses demonstrating reductions in hard endpoints such as vascular mortality and recurrent events after myocardial infarction or stroke. Aspirin has been a cornerstone therapy for cardiovascular prevention, particularly in secondary prevention among individuals with established atherosclerotic cardiovascular disease (ASCVD), where it reduces the risk of recurrent myocardial infarction, stroke, and vascular death by irreversibly inhibiting cyclooxygenase-1 (COX-1) to prevent platelet aggregation.[50] Daily dosing is recommended to maintain consistent and steady suppression of platelet function. Aspirin's antiplatelet effect is irreversible and lasts for the lifespan of the affected platelet (approximately 7–10 days), but new platelets are continuously produced. Daily administration ensures ongoing inhibition of newly formed platelets, providing more reliable protection against thrombotic events. Every-other-day dosing, while explored in some older primary prevention trials (such as the Physicians' Health Study using 325 mg every other day), is generally not considered as effective as daily low-dose regimens in modern practice, particularly for secondary prevention, as it may permit partial recovery of platelet aggregability between doses. Current AHA/ACC guidelines specify daily low-dose aspirin for secondary prevention to optimize efficacy while minimizing risks. In contrast, its role in primary prevention—among those without prior ASCVD—has evolved, with recent evidence indicating that the modest reduction in ischemic events is often offset by increased bleeding risks, leading to more selective recommendations.[5] Low-dose regimens, typically 75–100 mg daily, are standard for both contexts to balance efficacy and safety.[51] For secondary prevention, aspirin's benefits were firmly established by the ISIS-2 trial, a landmark randomized controlled trial involving 17,187 patients with suspected acute myocardial infarction, which showed that oral aspirin (162.5 mg daily) reduced 5-week vascular mortality by 23% compared to placebo (9.0% vs. 11.8%; p<0.00001), with additive effects when combined with streptokinase.[50] A subsequent collaborative meta-analysis by the Antithrombotic Trialists' Collaboration, pooling data from 16 secondary prevention trials with over 17,000 patients, confirmed a 25% proportional reduction in serious vascular events (nonfatal myocardial infarction, nonfatal stroke, or vascular death; 6.7% annual event rate with aspirin vs. 8.2% with control; p<0.0001), establishing aspirin as a foundational antiplatelet agent.[50] Current guidelines from the American Heart Association (AHA) and American College of Cardiology (ACC), updated in 2023 for chronic coronary disease management, recommend indefinite low-dose aspirin therapy (class 1 recommendation) for most patients with ASCVD, including post-myocardial infarction or revascularization, barring contraindications like recent major bleeding or high-risk features.[50] In patients with diabetes and a history of ASCVD, the American Diabetes Association's Standards of Care in Diabetes—2026 similarly recommends low-dose aspirin (75–162 mg/day) for secondary prevention, typically used lifelong unless contraindicated. Additionally, dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) is recommended post-acute events such as acute coronary syndrome, stroke, or transient ischemic attack, with duration determined by specialists.[52] Dosing comparisons, such as 81 mg versus 325 mg daily, show equivalent efficacy in reducing recurrent events without differences in major bleeding rates.[53] In primary prevention, early evidence from the 2009 Antithrombotic Trialists' meta-analysis of six trials involving 95,000 participants suggested a smaller 12% reduction in serious vascular events (0.51% annual absolute risk reduction; rate ratio 0.88, 95% CI 0.82–0.94), but with a doubling of major extracranial bleeding (0.10% annual absolute increase; rate ratio 1.54, 95% CI 1.30–1.82).[50] However, three large contemporary trials—ASPREE (16,703 elderly participants ≥70 years), ARRIVE (12,546 moderate-risk adults), and ASCEND (15,480 adults with diabetes)—collectively demonstrated no significant net benefit: ASPREE found no reduction in composite cardiovascular events (hazard ratio 0.95, 95% CI 0.83–1.08) but a 38% increase in major bleeding (hazard ratio 1.38, 95% CI 1.18–1.62); ARRIVE showed similar null results for the primary composite endpoint (hazard ratio 0.96, 95% CI 0.81–1.13) with doubled gastrointestinal bleeding; and ASCEND reported a 12% reduction in serious vascular events (hazard ratio 0.88, 95% CI 0.79–0.97) but a 29% increase in major bleeding (hazard ratio 1.29, 95% CI 1.09–1.52), resulting in no difference in net clinical benefit.[54] These findings prompted the U.S. Preventive Services Task Force (USPSTF) 2022 update, which recommends against initiating low-dose aspirin for primary prevention in adults aged 60 years or older (grade D) due to bleeding harms exceeding ischemic benefits, and suggests individualized decisions for those aged 40–59 years with a 10-year ASCVD risk ≥10% (grade C; small net benefit), emphasizing shared decision-making on bleeding risks.[5] For individuals with diabetes, the American Diabetes Association's Standards of Care in Diabetes—2026 indicate that low-dose aspirin (75–162 mg/day) may be considered for primary prevention in those at increased cardiovascular risk (e.g., age ≥50 years with additional risk factors like hypertension or dyslipidemia) after shared decision-making on benefits versus bleeding risk, with duration ongoing based on individualized assessment.[52] As of February 2026, no new guidelines on aspirin for primary prevention of cardiovascular disease were issued in 2025 or 2026, and the 2022 USPSTF guideline remains the current authoritative recommendation. The 2019 ACC/AHA guideline suggests low-dose aspirin might be considered (Class IIb) for select adults 40-70 years at higher ASCVD risk without increased bleeding risk, but the USPSTF 2022 is more recent and widely referenced.[55] Population-level trends reflect this shift, with U.S. aspirin use for primary prevention declining from 20.6% in 2019 to 15.7% in 2023, consistent with trends in 2025 publications showing declining aspirin use for primary prevention following the 2022 update.[56] Overall, while aspirin's role in secondary prevention remains robust, primary prevention is now reserved for carefully selected high-risk individuals without elevated bleeding potential.[51] Cancer Prevention Aspirin has been investigated extensively for its potential role in primary cancer prevention, particularly in reducing the incidence of colorectal cancer (CRC) through long-term use. Multiple randomized controlled trials (RCTs) and meta-analyses have demonstrated that regular aspirin intake, typically at low doses (75-325 mg daily), is associated with a reduced risk of CRC development, with benefits emerging after several years of use. For instance, a long-term follow-up of five RCTs involving over 14,000 participants showed that 5-10 years of aspirin use reduced the 20-year risk of CRC incidence by 24% (hazard ratio [HR] 0.76, 95% CI 0.60-0.96) and CRC mortality by 49% (HR 0.51, 95% CI 0.35-0.74).[57] This effect is attributed to aspirin's anti-inflammatory properties, which inhibit prostaglandin synthesis and COX-2 expression in colonic tissues, though detailed mechanisms are covered elsewhere. However, the overall benefit for total cancer incidence across all sites remains modest or inconsistent in broader meta-analyses, with one review of 29 RCTs (200,679 participants) finding no significant reduction (relative risk [RR] 1.01, 95% CI 0.97-0.04).[58] Evidence is strongest for CRC prevention in average-risk populations and those with hereditary predispositions. A 2020 meta-analysis of 118 observational studies across 18 cancer types reported a 27% reduction in CRC incidence (HR 0.73, 95% CI 0.69-0.78) with consistent aspirin use, with dose-dependent effects: 75-100 mg/day yielding a 10% risk reduction and 325 mg/day a 35% reduction. In high-risk groups, such as individuals with Lynch syndrome, the CAPP2 trial (861 participants) demonstrated that 600 mg daily aspirin for at least 2 years reduced CRC incidence by 63% over 55 months (HR 0.37, 95% CI 0.11-1.26). The 2025 CaPP3 trial (1,879 participants) further confirmed that low-dose aspirin (75-100 mg daily) reduces CRC risk by approximately 50% in Lynch syndrome patients, with efficacy comparable to higher doses and leading to updated UK guidelines (e.g., NICE) recommending daily low-dose aspirin (75-100 mg) for this population to balance benefits and bleeding risks.[59] Recent network meta-analyses (2023-2025) reinforce low-dose aspirin's superiority over placebo or higher doses for preventing CRC and adenoma recurrence, with one 2024 analysis of 13 RCTs showing low-dose (<300 mg/day) aspirin reducing adenoma risk more effectively than high-dose (RR 0.68 vs. 0.82). A 2025 meta-analysis of cohort studies further supported a 15-20% overall reduction in cancer incidence, driven primarily by gastrointestinal sites.[60] Beyond its role in reducing CRC incidence, low-dose aspirin has been associated with a decreased risk of cancer metastasis, particularly in colorectal cancer. A pooled analysis of randomized trials showed that daily aspirin use reduced the risk of distant metastasis by 36% among patients with incident cancers. Low-dose aspirin (typically 75-100 mg daily, up to 300 mg in some studies) has been linked to this effect, which is mediated by inhibition of platelet activation, reduction of thromboxane A2 (TXA2), and enhancement of T cell anti-metastatic immunity. In addition, adjuvant aspirin at 160 mg daily has been shown to reduce recurrence rates in colorectal cancer patients with alterations in the PI3K pathway. However, due to the increased risk of bleeding complications and variable evidence across populations, aspirin is not a standard recommendation for preventing cancer metastasis or recurrence.[61][62][63] For other cancers, the evidence is weaker and less consistent. Aspirin shows potential for reducing esophageal, gastric, and pancreatic cancer risks, with meta-analyses indicating 20-30% reductions in incidence (e.g., RR 0.72 for esophageal cancer in a 2023 umbrella review of RCTs and cohorts), but no clear benefits for breast, prostate, or lung cancers. Recent observational studies have provided additional evidence specifically for pancreatic ductal adenocarcinoma (PDAC). A 2024 nested case-control study using UK Biobank data found that regular aspirin use was associated with a 20% reduced risk of PDAC overall (OR 0.80, 95% CI 0.68-0.95) and a 40% reduced risk in participants with diabetes (OR 0.60, 95% CI 0.42-0.85).[64] A 2025 retrospective cohort study in Hong Kong patients with type 2 diabetes mellitus reported a 39-42% lower risk of pancreatic cancer with aspirin use (aHR 0.58, 95% CI 0.49-0.69 in time-dependent analysis; aHR 0.61, 95% CI 0.48-0.77 in propensity-score matching).[65] These findings suggest potential chem